The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global sepsis diagnostics market is expected to exhibit a CAGR of 9.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Sepsis is a medical condition caused due to the body’s response to fight infections that are based on contamination with bacteria, viruses, or fungi. In this condition, the immune system releases several chemicals into the bloodstream that trigger hyper inflammation and the formation of blood clots in the body. Sepsis may result in multiple organ failures, irregular breathing, low blood pressure, neurological dysfunction, faster heart rate, etc. The diagnostic procedures for sepsis primarily include molecular diagnosis, immunoassays, microfluidics, biomarkers, flow cytometry, etc. These diagnostic technologies are widely adopted across hospitals, pathology and reference laboratories, academic research institutes, etc.
The growing prevalence of hospital-acquired infections (HAIs) that causes sepsis, particularly among the geriatric population, infants, and patients suffering from chronic illness, is currently driving the demand for sepsis diagnostics. Furthermore, the rising incidences of numerous infectious diseases caused due to antibiotic-resistant bacteria, including gram-positive bacteria and gram-negative bacilli, are also propelling the need for sepsis diagnostics. Additionally, the expanding healthcare sector along with the increasing penetration of advanced data analytics tools is further catalyzing the sepsis diagnostics market growth. These data analytics tools have enabled the integration of multiple test results from diverse platforms, thereby providing real-time data access and accurate disease diagnosis. Moreover, several technological advancements have led to the emergence of novel immunological and molecular biomarkers that enable the early detection of sepsis. In line with this, the rising investments in extensive R&D activities that include new blood culture approaches for identifying and treating chronic infections are also driving the market for sepsis diagnostics.
IMARC Group provides an analysis of the key trends in each sub-segment of the global sepsis diagnostics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on diagnosis, product, mode of testing, technology, pathogen and end user.
Breakup by Diagnosis:
Breakup by Product:
Breakup by Mode of Testing:
Breakup by Technology:
Breakup by Pathogen:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Becton, Dickinson and Company (BD), biomerieux SA, Bruker Corporation, EKF Diagnostics Holding Plc, Epic Systems Corporation, Luminex Corporation, Roche Holding AG, Sysmex Corporation, and T2 Biosystems Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Diagnosis, Product, Mode of Testing, Technology, Pathogen, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, Australia, Singapore, Brazil, Mexico, Argentina, Saudi Arabia, United Arab Emirates, South Africa|
|Companies Covered||Abbott Laboratories, Becton, Dickinson and Company (BD), biomerieux SA, Bruker Corporation, EKF Diagnostics Holding Plc, Epic Systems Corporation, Luminex Corporation, Roche Holding AG, Sysmex Corporation, and T2 Biosystems Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at